Mark Arya

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer et al. · The Lancet Infectious Diseases · 2022 · 81 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study

Megan N. Landis, Mark Arya, Stacy Smith et al. · British Journal of Dermatology · 2022 · 63 citations · Full text

Medicine, Dermatology, Pharmacology +16

A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults

James Baber, Mark Arya, Yuben Moodley et al. · The Journal of Infectious Diseases · 2022 · 46 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Eugene Athan, James Baber, Karen Quan et al. · Clinical Infectious Diseases · 2023 · 43 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults

Louise Murdoch, Karen Quan, James A. Baber et al. · Infectious Diseases and Therapy · 2023 · 24 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17